Description
Immunotherapeutic approach for treatment of advanced hepatocellular carcinoma: a systematic review. Dmitrii Shek 1,2,3, Scott A. Read 1,2,3, Adnan Nagrial 4, Matteo S. Carlino 4, Bo Gao3, Golo Ahlenstiel 1,2,3 1. Blacktown Clinical School and Research Centre, Western Sydney University, Blacktown, NSW, Australia 2. Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, Australia 3. Blacktown Hospital, Blacktown, NSW, Australia 4. Westmead Hospital, Westmead, NSW, Australia Background Hepatocellular carcinoma (HCC) is a primary liver malignancy. Kinase inhibitors are standard of care (SoC) for metastatic HCC with median overall survival (mOS) of
Speaker(s):
